• Rank	Status	Study
  1	Completed	Evaluating an Ebola and a Marburg Vaccine in Uganda Conditions: Ebola Virus Disease;   Marburg Virus Disease Interventions: Biological: Ebola vaccine;   Biological: Marburg vaccine;   Other: Placebo injection
  2	Not yet recruiting	Phase 1 Trial of Ebola Vaccine in Mali Conditions: Ebola Virus Disease;   Hemorrhagic Fever Intervention: Biological: Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z)
  3	Recruiting	A Study to Assess a New Ebola Vaccine, cAd3-EBO Z Conditions: Ebola;   Ebola Zaire Interventions: Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp
  4	Completed	Experimental Vaccine for Prevention of Ebola Virus Infection Conditions: Ebola Hemorrhagic Fever;   Ebola Virus Disease;   Ebola Virus Vaccines;   Envelope Glycoprotein, Ebola Virus;   Filovirus Intervention: Drug: VRC-EBOADV018-00-VP
  5	Completed	Ebola and Marburg Virus Vaccines Conditions: Ebola Vaccines;   Marburg Virus Disease;   Ebola Virus Disease;   Marburgvirus;   Ebolavirus Interventions: Drug: VRC-EBODNA023-00-VP;   Drug: VRC-MARDNA025-00-VP
  6	Completed	Experimental Ebola Vaccine Trial Conditions: Hemorrhagic Fever, Ebola;   Healthy Intervention: Drug: VRC-EBODNA012-00-VP
  7	Recruiting	Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults Condition: Healthy Adult Immune Responses to Vaccine Intervention: Biological: VRC-EBOADC069-00-VP
  8	Completed	Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus Condition: Ebola Hemorrhagic Fever Interventions: Drug: Placebo;   Drug: AVI-6002
  9	Terminated	Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion Condition: Ebola Virus Infection Interventions: Drug: TKM-100201;   Drug: Placebo
  10	Withdrawn	A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers Condition: Ebola Hemorrhagic Fever Interventions: Drug: AVI-7537;   Other: Normal Saline Solution (NSS)
  11	Suspended	Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802 Condition: Ebola Virus Infection Interventions: Drug: TKM-100802 for Injection;   Drug: Placebo
  12	Completed	Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study Conditions: Influenza;   Severe Acute Respiratory Distress Syndrome;   Smallpox;   Ebola;   Unknown Respiratory Viruses Intervention: Drug: Poly-ICLC
  13	Completed	VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases Condition: Healthy Intervention:

  
  

• Acute Lung Injury   1 study

• Acute Respiratory Distress Syndrome   1 study

• Adenoviridae Infections   2 studies

• Communicable Diseases   11 studies

• Coronary Artery Disease   3 studies

• Coronary Disease   3 studies

• Ebola Virus Disease   9 studies

• Fever   10 studies

• Hemorrhagic Fever   10 studies

• Hemorrhagic Fever, Ebola   10 studies

• Hemorrhagic Fevers, Viral   10 studies

• Infant, Newborn, Diseases   1 study

• Infant, Premature, Diseases   1 study

• Infection   11 studies

• Influenza, Human   1 study

• Lung Diseases   1 study

• Lung Injury   1 study

• Marburg Hemorrhagic Fever   2 studies

• Marburg Virus Disease   2 studies

• Respiration Disorders   1 study

• Respiratory Distress Syndrome, Adult   1 study

• Respiratory Distress Syndrome, Infant   1 study

• Respiratory Distress Syndrome, Newborn   1 study

• Respiratory Tract Diseases   1 study

• RNA Virus Infections   9 studies

• Smallpox   1 study

• Syndrome   1 study

• Viral Hemorrhagic Fever   10 studies

• Virus Diseases   12 studies

http://clinicaltrials.gov/ct2/results/browse?term=Ebola&brwse=cond_alpha_all